KSV01 / TCRx Therap - LARVOL DELTA

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: TCRx Therapeutics Co.Ltd | N=30 ➔ 18 | Initiation date: May 2025 ➔ Sep 2025 | Trial primary completion date: Jun 2028 ➔ Dec 2028

Enrollment change • Trial initiation date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Zhejiang University

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: TCRx Therapeutics Co.Ltd

New P1 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology